Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study DOI Creative Commons

Xue Zhong,

Chao Wang,

Lin Huang

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 6, 2023

Background: The breakthrough development of novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in curtailing the spread pandemic dramatically reducing morbidity mortality rates among those infected. Among these antivirals, nirmatrelvir/ritonavir (NR) has been repurposed successfully for use against coronavirus disease-2019 (COVID-19) is now readily available on market with promising therapeutic effects. availability convenient effective NR treatments COVID-19 greatly mitigates severity epidemic contributes to an early end pandemic. Furthermore, certain patient subgroups, specifically rheumatic disease (RD) who are currently undergoing intensive immunodeficiency and/or immunosuppressive treatments, continue be vulnerable at higher risk experiencing consequences from COVID-19. Additionally, it also observed that exhibited prevalent drug-drug interactions clinical significance, more instances rebound were being recognized increasing frequency. Methods: A retrospective cohort study was conducted real-world RD population infected SARS-CoV-2 treated NR. time symptom resolution, length hospitalization, response rate assessed. Results compared standard regimen non-standard groups, late indication non-indication groups. During course, all grades adverse drug reactions (ADRs) directly associated administration (DDIs) monitored. Results: total 32 patients RD, received NR, retrospectively identified divided into different We found group had shorter median resolution control [9.0 (interquartile range [IQR], 8.3-11.3) vs. 21.5 (IQR16.0-24.0) days, p < 0.001 9.0 (IQR 23.0 18.0-24.0) = 0.0]. further even if exceeds 5 receive can still derive benefits it. proportion showed improvement (n 13/17 3/6, 76.5% 50.0%) follow-up, there statistical difference (p 0.0) between two analyzed effect comorbidities percentage <4 ≥ 4 7/7 16/25, 100.0% 64.0%) follow-up. ADRs grade ≥3ADRs not any cases. Despite discontinuing warfarin prior application (using immediately first day withdrawal), one experienced increased international normalized ratio [INR, 5.32(0.90-1.20)] coagulation disorders (weak positive fecal occult blood test) second after using INR levels decreased nearly normal values, returned 2 days (the seventh initial NR). Conclusion: therapy favorable outcome acceptable safety profile immunosuppressed during Omicron surge. Early (within onset) could improve prognosis patients. symptoms confirmed infection >5 may mitigate progression viable strategy. Our results highlight importance utilization indication, which yield advantages SARS-CoV-2.

Language: Английский

Nanoparticle-Based Drug Delivery for Infectious Diseases DOI
Ashrafi Sultana, Mohammad Ullah Nayan

Published: Jan. 1, 2024

Language: Английский

Citations

0
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge DOI
Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini

et al.

Journal of Chemotherapy, Journal Year: 2023, Volume and Issue: 36(4), P. 283 - 290

Published: Dec. 14, 2023

Among treatment options for Coronavirus disease 2019 (COVID-19), monoclonal antibodies (mAbs) showed to be effective in preventing progression, but real-world data during the Omicron variant surge are still lacking. Multicentre retrospective study evaluating effectiveness of sotrovimab and casirivimab-imdevimab fragile patients with mild SARS-CoV-2 infection between November 2021 March 2022. Unfavourable outcome was defined as increased need oxygen supplementation and/or death. Of 268 study-participants, 12 (4.48%) previously needed supplemental oxygen, while 6 (2.24%) had active solid neoplasia (2.24%); 186 (69%) have received vaccination. Overall, 22 (8%) unfavourable outcomes (42% versus 6% without previous 50% 7% neoplasia). Both therapy before malignant tumour shown risk factors failure. Log-rank test did not identify differences treatment. Despite diffusion variant, rate higher than expected. The presence underlying factors, including cancer independently associated COVID-19 suggesting antiviral treatments limited mAbs implementation vaccine campaign.

Language: Английский

Citations

1
Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study DOI Creative Commons

Xue Zhong,

Chao Wang,

Lin Huang

et al.

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 6, 2023

Background: The breakthrough development of novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines and oral antivirals have played a critical role in curtailing the spread pandemic dramatically reducing morbidity mortality rates among those infected. Among these antivirals, nirmatrelvir/ritonavir (NR) has been repurposed successfully for use against coronavirus disease-2019 (COVID-19) is now readily available on market with promising therapeutic effects. availability convenient effective NR treatments COVID-19 greatly mitigates severity epidemic contributes to an early end pandemic. Furthermore, certain patient subgroups, specifically rheumatic disease (RD) who are currently undergoing intensive immunodeficiency and/or immunosuppressive treatments, continue be vulnerable at higher risk experiencing consequences from COVID-19. Additionally, it also observed that exhibited prevalent drug-drug interactions clinical significance, more instances rebound were being recognized increasing frequency. Methods: A retrospective cohort study was conducted real-world RD population infected SARS-CoV-2 treated NR. time symptom resolution, length hospitalization, response rate assessed. Results compared standard regimen non-standard groups, late indication non-indication groups. During course, all grades adverse drug reactions (ADRs) directly associated administration (DDIs) monitored. Results: total 32 patients RD, received NR, retrospectively identified divided into different We found group had shorter median resolution control [9.0 (interquartile range [IQR], 8.3-11.3) vs. 21.5 (IQR16.0-24.0) days, p < 0.001 9.0 (IQR 23.0 18.0-24.0) = 0.0]. further even if exceeds 5 receive can still derive benefits it. proportion showed improvement (n 13/17 3/6, 76.5% 50.0%) follow-up, there statistical difference (p 0.0) between two analyzed effect comorbidities percentage <4 ≥ 4 7/7 16/25, 100.0% 64.0%) follow-up. ADRs grade ≥3ADRs not any cases. Despite discontinuing warfarin prior application (using immediately first day withdrawal), one experienced increased international normalized ratio [INR, 5.32(0.90-1.20)] coagulation disorders (weak positive fecal occult blood test) second after using INR levels decreased nearly normal values, returned 2 days (the seventh initial NR). Conclusion: therapy favorable outcome acceptable safety profile immunosuppressed during Omicron surge. Early (within onset) could improve prognosis patients. symptoms confirmed infection >5 may mitigate progression viable strategy. Our results highlight importance utilization indication, which yield advantages SARS-CoV-2.

Language: Английский

Citations

0